I Teknikurn, Uppsala University, Box 534, 5-751 21 Uppsala, Sweden; and 2Department of Surgery, University Hospital, S-751 85 Uppsala, Sweden. Sary Swedish population-based incidence and mortality rates for cancer of the uterine cervix, both in situ and invasive, during the period 1958 to 1981 were determined by means of a dynamic model. This new approach describes without any preconceptions the development of the disease as a sequential process over the stages cancer in situ, invasive cancer before and after diagnosis, and death. The strong disurbance of the steady-state situation that occurred after the introduction of cytological mass screening in the early 1960s permitted the use of a computerized identification technique. The whole natural history of cervical cancer could thus be identified and described consistently, with the mutual compatibility between statistical data, structure, parameters, and the states and flows between the states. The estimated age-specifc incidence of cancer in situ increased rapidly to a maximum of 650 per 105 woman-years at the age of 30 years, after which it declined, and that of invasive cancer to a maximum of 55 per 105 at the age of 43. The natural history of cervical neoplasia did not differ appreciably between eight successive 5-year birth cohorts. The proportion of cases of new cancer in situ that progressed to invasive cancer was 12.2%, with a mean duration of the in situ stage in these cases of 13.3 years. The precinical phase of the invasive stage (without screening) lasted on average about 4 years.
Cytological screening for cancer of the uterine cervix has been widely performed throughout the western world since the early 1960s (Canadian Task Force on Screening, 1976; Bourne & Grove, 1983; Hakama et al., 1985; Duguid et al., 1985; Pettersson et al., 1985; Robra et al., 1985; Liri et al., 1987) and it is now generally accepted that the mortality rate from cancer of the cervix has declined as a result of the screening measures (Kessler, 1974; Bourne & Grove, 1983; Duguid et al., 1985; Hakama et al., 1985; Pettersson et al., 1985; Robra et al., 1985; IARC Working Group, 1986 ). This conclusion, however, remained controversial during many years for two major reasons, namely the lack of randomised trials and the deficient knowledge about the natural history of cervical neoplasia. It seems to be generally accepted that invasive cancer of the uterine cervix is preceded in most or all instances by a preinvasive (in situ) stage (Boyes et al., 1982) . Data on the age-specific incidence of cancer in situ are largely lacking and there are only few and contradictory estimates of the proportion of in situ cancers that actually progress to the invasive form and of the time constants in the evolution from preinvasive cancer to clinical diagnosis (Kessler, 1974; Boyes et al., 1982; Knox, 1982) . It is also unknown whether these parameters are associated with the woman's age.
Beyond its obvious interest from a tumour-biological point of view, a clear picture of the natural history of cervical neoplasia would probably facilitate cost-effective designing of screening interventions and might eventually minimise overtreatment of preinvasive cancers that otherwise would not have progressed to an invasive stage. In most instances, however, ethical constraints prohibit studies on the untreated progress of premalignant and malignant diseases. Advancement of knowledge in this area -which has even been considered impossible (Kessler, 1974; Draper & Cook, 1983) -therefore requires other approaches than those traditionally used in medical research (Knox, 1982) . Examples of such alternative approaches are simulation techniques (Bigelow, 1975; Coppleson & Brown, 1975; Knox, 1975 ; Barron et al., 1978; Eddy & Shwartz, 1982; Yu et al., 1982; Habema et al., 1983 , Parkin, 1985 Parkin & Moss, 1986) .
From the field of control theory it is well known that the parameters of a system can be calculated provided that its structure is known and that the system is disturbed. In this Correspondence: L. Gustafsson. study, the access to suitable simulation languages and mathematical packages (Pugh, 1976; Wait & Clark, 1977; The IMSL Library, 1982; Gustafsson, 1983 ) facilitated our approach which consisted of the use of an identification technique. In addition, favourable prerequisites were offered in Sweden through the availability of reliable incidence (Cancer Incidence in Sweden, 1960 Sweden, -1984 and mortality (Causes of Death 1958 -1981 rates for cancer of the uterine cervix over a 24-year period for the entire population of about four million women, and through the extensive screening programme that was introduced in Sweden during the early 1960s (National Board of Health and Welfare, 1982) .
The purpose of this study was to investigate the natural history of cervical neoplasia in terms of the states cancer in situ, preclinical invasive cancer and invasive cancer after diagnosis, and death, and the flows to, between and from these states. A dynamic model which describes how these states and flows are related was constructed.
We have tried to facilitate the reading of this paper by keeping the presentation of technical aspects at a minimum and presenting them in appendices. Detailed information may, however, be of decisive importance for a critical assessment of the internal validity of the study. An extensive methodological presentation is therefore available on request (Gustafsson, 1986) .
Badgoun and material
Cytological screening Cytological screening for cervical cancer with Papanicolaou smears started in Sweden in the early 1960s, and organised population-based programmes were successively introduced during the period 1%7-1973 (National Board of Health and Welfare, 1982; Pettersson et al., 1985) . Women aged 30-49 years were invited to undergo cytological screening at 4-year intervals. The extent of the organised screening was limited, however, and the rate of participation was low until the end of the 1960s, with only about 9,000 examinations in 1%7. The total annual number of smears -within and outside the organised screening -then increased rapidly to about one million in 1970 and thereafter (National Board of Health and Welfare, 1982) . Less than one-quarter of the smears have been taken within the organised screening and the remainder outside this scheme at hospitals and outpatient Br. J. Cancer (I989), 60, [132] [133] [134] [135] [136] [137] [138] [139] [140] [141] clinics (National Board of Health and Welfare, 1982) . By all these means, which are denoted 'screening measures' in the following text, a large number of cases of cancer in situ have been detected (Figure 1) Sweden, 1960 Sweden, -1984 . It is obligatory for all physicians in hospitals and other establishments for medical treatment in Sweden to report to the National Cancer Registry all cases of diagnosed cancer. In addition, pathologists and cytologists separately report every cancer diagnosis based on surgically removed tissues, biopsies, cytological specimens and autopsies to the registry. This obligation to report also includes cancer in situ of the cervix uteri. The frequency of underreporting to the registry has been estimated to be 0.7% for cancers of the female genital organs (Mattsson & Wallgren, 1984) . Swedish population-based mortality statistics, which are published annually, cover the entire period of cancer registration (Causes of Death, 1960 -1983 Sweden, 1960 Sweden, -1984 ; (3) the number of deaths due to cervical cancer (Causes of Death, 1960 -1983 ; (4) the number of women of different ages (National Central Bureau of Statistics, 1959 Statistics, -1983 .
During the period 1958-1981 the total number of reported cases of cancer in situ was 64,215, of invasive cancer 18,218 and of deaths due to cancer of the uterine cervix 6,990 (Figure 1) . From the population statistics the number of women at risk was calculated as the average of the number at the beginning and at the end of each year.
The number of detected cases with cancer in situ and with invasive cancer and the number of deaths per year are shown in Figure 1 . After the end of the 1960s the incidence of in situ cases found at screening was about five times that of invasive cases diagnosed before screening measures were undertaken, showing that only a small proportion of the cancer in situ cases progressed. The surplus number of invasive cancer and the number of deaths per year are shown detection at screening is also evident (Figure 1 ). The screening effects are illustrated by age in Figure 2, Figure 3 are defined in Appendix I and will be used in the following text in order to be exact and avoid confusion.
The number of in situ cases that are detected (SCR) is highly dependent on the extent of cytological screening, and the true incidence of cancer in situ (INS) is unknown. The in situ box has a more detailed inner structure than is shown in Figure 3 . After extensive studies, a three-box structure was found to give the most appropriate description of the in situ stage. These investigations are discussed further below.
Invasive cancers have a preclinical phase during which nothing is known and registered and -after detection -a clinical phase during which the woman is a patient and can be followed up (Figure 3 ). In the absence of screening, most diagnosed cervical neoplasms are in the invasive stage, whereas during screening a much greater number of in situ (SCR) than of invasive (DIAG+DIAGSCR) cancers are detected. The incidence flows of invasive cancers that surface clinically (DIAG) and those of such cancers that are detected at screening (DIAGSCR) cannot be separated on the basis of the statistics from the Cancer Registry (Cancer Incidence in Sweden, 1960 Sweden, -1984 . It is these invasive cancers which were found earlier as a result of screening that cause the 'bump' in the invasive curve of Figure 1 .
The model also includes a number of unknown parameters. These are the sojourn times: T1, T2 and T3 in the states of IN SITU, INV PRECLIN and INV CLIN respecti- vely, and the proportion (P) of new in situ lesions that without therapeutic measures would become invasive, and finally the proportion (Q) of patients with invasive cancer who will die of cancer of the cervix uteri. These parameters are also shown in Figure 3 and exactly defined in Appendices I and 2.
Estimating these parameters gives a unique model by which all the flows and states can easily be calculated.
Statistical preprocessing
Cohort data The original data, obtained from official Swedish statistics (Causes of Death, 1960 -1983 National Central Bureau of Statistics, 1959 Statistics, -1983 Cancer Incidence in Sweden, 1960 -1984 for each year and each 5-year age group were compiled and entered into matrices of in situ and invasive diagnoses, death and population. For technical reasons it was appropriate to divide the in situ and invasive diagnoses and death matnrces by the population matrix and multiply by 105, which meant that we got three age-specific matrices. In this context we wanted to distort the information as little as possible and obtain smoothed data that were unbiased over time. For this reason a 3-year average was used, creating a new matrix from the old one, where each new value was obtained as:
This means that the three terms X(t -1), X(t), and X(t + 1) all refer to the same age but are sampled in three consecutive years.
In order to study the effects of screening, which commenced in Sweden in the mid-sixties, we chose to analyse the eight 5-year birth cohorts born between 1904 and 1943. Of these cohorts, the six youngest had been heavily exposed to screening measures, whereas the two oldest had been only slightly exposed. The eight cohorts were of ages 50-54, 45- 49 and so on in 1958, with the youngest 15-19 years old. They represented about two million women, including totals of 38,969 women with cancer in situ, 13,830 women with invasive cancer and 4,784 deaths due to cancer of the uterine cervix during the 24-year study penrod. As a result we now had the necessary statistics, which we denote SCRSTAT for diagnoses of cancer in situ, DIAGSTAT for diagnoses of invasive cancer and MORTSTAT for mortality from cervical cancer, expressed per 105 women-years as based on cohort data. In Figure 4 the numbers of diagnoses of invasive cancer from 1958 through 1981 are shown for the eight cohorts of this study.
Steady-state references To calculate the way in which screening affects the annual number of diagnosed cases of invasive cancer and of deaths, information was required both for the situation without and for that with screening. We therefore first calculated, as references. the annual numbers for the situation when the system was not disturbed by screening measures.
Reference for incidence rates It is evident from the incidence rates of cancer in situ in the Cancer Registry that between 1958 and 1963 the degree of screening was insignificant ( Figure 1 ). Moreover, only few of those cases detected at screening during [1964] [1965] [1966] [1967] Figure 5 . In this figure the reference (DIAGREF) of age-specific incidence rates was constructed and denoted with a solid line.
Reference for mortality rates In the same way as DIAGREF (see above), a reference for mortality rates (MORTREF) was derived from the mortality rates for the cohorts (MORTSTAT) in 1958-1967.
Identification
The way in which screening measures affect the whole system is illustrated in Figure 3 in a reduction of the flow of diagnosed invasive cancers (DIAG) which is lagging and dispersed in time. The magnitude of this reduction should be the difference between DIAGREF and (DIAG + DIAGSCR). Still later the disturbance will influence the mortality rates by a magnitude of MORTREF-MORT. This gives the opportunity to use identification technique on the prediagnosis submodel to estimate the parameters P, TI and T2 and the INS-function in a least square sense, and on the post-diagnosis submodel to estimate the parameters Q and T3. (For further description of identification, see Appendix 3).
Validation
The validation work with its many technical aspects has been extensively presented by Gustafssf (1986) and is only bnrefly discussed here. This work included a large number of tests of various hypotheses, structures and methods of investigation; various tools for data handling, modelling, simulation and identification were also tested.
Structure Validation of the hypotheses concerning structure referred to the evolution of the disease during the in situ phase and consequently to the way in which the in situ structure should be modelled. The knowledge available about this phase was too vague to be used. After testing a number of different inner structures of the in situ stage, a third order description was chosen; this gave an overall performance of the model which was in accordance with the statistical data. This inner description of the in situ stage complicated the modelling work concerning regression and screening flows. Different assumptions about the proportions of these flows that come from the three substages had to be tested. However, it was shown that these different assumptions had a very minor effect on the performance of the model (Gustafsson, 1986) .
Data validation The statistics used in this study referred to the whole female population in Sweden, which meant a large number of cases. We considered the validity and completeness of these data (Mattsson & Wallgren, 1984) to be high, probably the best obtainable. In addition, all women can be followed up over long periods of time through linkage to the unique national registration number. The statistics for screening, invasive diagnoses, deaths and population were produced yearly for women divided into 5-year age groups, which gave a resolution that was high enough for our purposes.
When constructing the references for the situation without screening measures, we used statistics for the years [1958] [1959] [1960] [1961] [1962] [1963] [1964] [1965] [1966] [1967] in spite of the fact that screening had commenced some years earlier. We argued that until 1967 the effects would have been negligible. To test this assumption we investigated the passage over time of cases from SCR to DIAG and from SCR to MORT, respectively (Figure 3) . The results supported the assumption that screening effects were negligible between 1958 and 1967 (Gustafsson, 1986) .
Temporal trends In the identification of the effects of screening measures, it was implicitly assumed that otherwise the system would have remained in -or close to -a 'steady state'. We therefore had to analyse the possible impact of any incidence trends during the years . The assessment of such trends was based on statistical data that were not affected by screening, namely: (1) data from the years 1958-1967 when screening had not yet affected the DIAG and MORT flows; (2) old birth cohorts who had never been exposed to screening; and (3) young birth cohorts before the onset of screening effects.
Among women younger than 70 years there was virtually no change in the incidence of cervical cancer during the period 1958-1967. Older birth cohorts, which were largely uninfluenced by screening, displayed a negligible upward trend during the period 1958-1981. A trend toward increased age-specific incidence rates emerged for the youngest cohorts -especially among cohorts younger than those included in this study. The main result, however, was that it seemed unlikely that any trend would have been of such an order as to disturb significantly the parameter estimates (Gustafsson, 1986) .
Results
Results from the prediagnosis sub-model Parameters All the cohorts showed similar results, with surprisingly small variations in the parameter estimates (Table I ). An (Table I) .
It is not known whether invasive and in situ cancers are discovered with the same sensitivity at a cytological investigation. In the first approach we included the ratio of the sensitivity in diagnosing invasive cancer (Si,) to the sensitivity in diagnosing cancer in situ (Si,) Figure 3 ) and no screening measures are taken, the number of diagnoses of invasive cancer will be equal to the reference obtained from incidence rates before screening (DIAGREF).
The calculated age-specific incidence of cancer in situ is illustrated in Figure 7 With screening In order to obtain the post-diagnosis parameters by identification of the cohorts, the same procedure as for the prediagnosis identification was carried out. As input, the optimal DIAG and DIAGSCR from the prediagnosis identification were used. The opfimisation process for minimising MORT-MORTSTAT for each cohort gave the results presented in Table Ill (Coppleson & Brown, 1975; Knox, 1975; Yu et al., 1982; Parkin, 1985; Parkin & Moss, 1986) . In this study we only used a simulation package to solve the differential equations. Thus all the parameters, including degree of regression, were uniquely calculated by comparison with known statistics. In most Markov models the number of parameters is much higher than that obtainable from statistical data. Statistical models, on the other hand, often fail because they neglect the dynamic aspects. Many models also assume that the degree of regression from cancer in situ to normal is zero.
Our main task was to compare the behaviour of the model, with its given structure and unknown parameters, with the real behaviour described by incidence and mortality time series for various cohorts. By using an identification technique, known as parameter estimation, the set of parameters giving the best fit of the model behaviour to (Eykhoff, 1974; Box & Jenkins, 1970; Ljung, 1987 Koss, 1979) . The estimates of probabilities and transition times for sequential progression from one stage to the next have varied widely, however, and the resulting vague idea about the true incidence and untreated progression of in situ lesions has severely hampered a rational and cost-effective design of population-based screening measures (Kessler, 1974; Knox, 1982; Hakama et al., 1985) . The incidence of cancer in situ has been calculated in only few studies (Dunn & Martin, 1%7, Bibbo et al., 1971; Albert, 1981; Boyes et al., 1982; Parkin et al., 1982) . Parkin et al. (1982) derived the incidence rate of cancer in situ from the prevalence figures obtained at a second investigation after a cytologically normal smear.
Such an estimate does not account for the new lesions that regress to normal during the intervening period of time. This might partly explain the considerably lower figure of 69 per 105 reported by Parkin et al. (1982) than by us. The working hypothesis proposed in the British Columbia cohort study (Boyes et al., 1982) that the incidence of cancer in situ decreases rapidly after a peak at the age of 30-34 was largely confirmed in our analysis.
It has been unanimously shown in all studied populations -and was further emphasised by our data -that the cumulative incidence of cancer in situ is much higher than that of invasive cancer (Cancer Incidence in Sweden, 1960 -1984 . This observation is consistent with the low proportion (about 12%) of new in situ cases progressing from preinvasive to invasive cancer found in this study and the view that regression is an important part of the natural history of cancer in situ (Boyes et al., 1982) . It would be interesting to compare this result to what is found from other studies. It is, however, important to bear in mind that our estimate for the proportion of new cases in situ that progress to invasive cancer (which we found constant over age) cannot be directly compared to the proportion of prevalent in situ cases that progress. This last measure is of course a function of the INS curve and thereby of age, and also of the specific screening activity earlier applied to the population under study. We have no possibility to calculate the parameter P from previous studies. However, we can simulate from our own data the prevalence rate under different circumstances. Thus, with no screening measures, our study (with P= 12.2%) gives a proportion of prevalent in situ cases that progress to invasive cancer typically in the range of 15-23%.
This estimate is lower than in most previous publications. Although the range has varied from 25 to 70% (Petersen, 1956; Thorn et al., 1975) , it has been stated that progression occurs in 60% (Boyes et al., 1962) , in a substantial proportion (Coppleson & Brown, 1974; Koss, 1979) or even in the majority (Canadian Task Force on Screening, 1976; Albert, 1981) of untreated patients.
The probability of progression of new in situ cases was virtually about the same at all ages in this study. The slightly higher value in the youngest birth cohort (14.7%) was probably not due to chance or to a differing natural history in this group. A more likely explanation would be that the increasing incidence of invasive cancer in younger birth cohorts (Cook & Draper, 1984; Duguid et al., 1985) reflects a similar trend for in situ lesions as well.
The duration of the stage between transition from cancer in situ to invasive cancer is another controversial issue, the estimated mean duration varying from 1 to 30 years (Boyes et al., 1962; Fidler et al., 1968; Boyes & Worth, 1968; Kashgarian & Dunn, 1970; Coppleson & Brown, 1975; Canadian Task Force on Screening, 1976; Barron et al., 1978; Koss, 1979; Albert, 1981) . The approach used in this study to assess this quantity has not to our knowledge been used before, but more recent analyses based on different statistical techniques (Barron et al., 1978) have often yielded estimates relatively close to those obtained here, i.e. about 12-14 years (Table I) . The progression time from cancer in situ to invasive cancer showed no trend in relation to the different birth cohorts.
The natural course thus seems to be largely unrelated to the age at inception of the in situ stage, a conclusion that contradicts previous claims of slower (Dunn, 1953; Ashley, 1966; Coppleson & Brown, 1975; Hakama & Pentinnen, 1981; Prorok, 1986) or more rapid (Paterson et al., 1984) progression im younger women.
Development of invasive cancer de novo, i.e. without a preceding in situ stage, has been considered rare or unlikely (Canadian Task Force on Screening, 1976 ). In our model this would correspond to a progression time (T1) that approaches zero. The cumulative proportion of invasive cancer cases derived from the impulse response (Figure 6) actually suggested that very short progression times are infrequent; in the order of 10% of the cumulative number of invasive cancers developed within the first 5 years after entering the preinvasive stage.
The close agreement between model results and statistics does not support the postulated existence of two major types of cancer of the cervix with a definitely differing natural course (Bailar, 1961; Ashley, 1966; Albert, 1981; Hakama & Penttinen, 1981 The compartmental model is depicted in Figure 3 . To give the complete mathematical representation of the model, some information must be added. 
We can write (X denotes the time derivative of X):
If we regard the flows INS, SCRt, SCR2, SCR3 and DIAGSCR as inputs, we can write:
It is seen that for any values of S1, S2 and S3 the flows SCRI, SCR2 and SCR3 add up to SCRSTAT, which means that we have built a mechanism for distributing SCRSTAT proportionally to the respective INSITU levels. Our Eykhoff (1974) , Box & Jenkins (1970) and Ljung (1987) .
In Figure 8 . The difference in the outputs from the system and the model (V) over T years of a study is minimised in a least square sense as: lT min l=TJe2(t) dt, or, in a discrete form, as:
min where e(t) is the deviation between model output and corresponding statistics.
Our task was to find the set of parameters which would minimise the loss function V We then performed the identification, first of the prediagnosis and then of the postdiagnosis sub-model.
The first part was based on the course up to the diagnosis of invasive cancer, and the second part was based on the course from diagnosis of invasive cancer to death. In both cases the analyses were made on each of the eight cohorts.
Identification of the prediagnosis sub-model
The prediagnosis part of the model (Figure 3 ) starts with the flow of new in situ cases (INS) and of cases eliminated by screening measures (SCR), and ends with diagnoses of invasive cancer (DIAG and DIAGSCR). Our goal was to estimate for each of the eight cohorts in the study the proportion of new in situ lesions that progress to invasive cancer (P), the time constants for cancer in situ (Ti) 
